Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 11.6b

Immunosuppression Use for Induction by Discharge Regimen, 2005 to 2009

Recipients with Heart Transplants

  Discharge Regimen (w/ or w/o Steroids Use) All
CyA Tac CyA+ MMF Tac+ MMF CyA+ Aza Tac+ Aza Siro+ MMF CyA+ Siro Tac+ Siro Other
Functioning Graft with Immunosuppression Info at Discharge 95 322 2,526 6,045 154 136 65 7 66 663 10079
% of All Regimens 0.9% 3.2% 25.1% 60.0% 1.5% 1.3% 0.6% 0.1% 0.7% 6.6% 100.0%
Induction Drug
Atgam/NRATG/NRATS 6.3% 6.8% 4.7% 5.2% 11.7% 11.0% 9.2% 57.1% 9.1% 15.2% 6.1%
OKT3 3.2% 0.3% 2.7% 1.7% 30.5% 2.9% 1.5% 0.0% 3.0% 6.3% 2.7%
Thymoglobulin 9.5% 13.4% 14.3% 18.9% 16.2% 37.5% 29.2% 14.3% 57.6% 25.2% 18.4%
Zenapax 6.3% 2.5% 20.9% 10.9% 3.2% 2.9% 6.2% 0.0% 1.5% 32.0% 14.1%
Simulect 12.6% 12.1% 14.1% 15.3% 7.8% 5.1% 16.9% 28.6% 3.0% 25.6% 15.3%
Campath 4.2% 12.7% 0.2% 2.8% 0.6% 0.0% 10.8% 0.0% 0.0% 3.6% 2.5%
No Induction Drugs Recorded 61.1% 53.7% 44.6% 47.9% 30.5% 41.2% 32.3% 28.6% 28.8% 47.7% 46.8%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.